Suscribirse

Prevalence of multiple system atrophy: A literature review - 25/05/24

Doi : 10.1016/j.neurol.2023.11.013 
S. Kaplan
 Teva Pharmaceutical Industries Ltd, 12, Hatrufa St, Netanya, Israel 

Highlights

The majority of MSA epidemiological studies were mainly conducted in Europe and few were conducted in Brazil, Japan and the USA.
MSA prevalence studies were mainly prospective population-based studies or multi-center studies.
The estimated crude prevalence of MSA ranged from 0.52–17/100,000 persons and was higher among men than women (2.75 vs. 1.19 per 100,000 persons)
Age-specific prevalence rates varied and increased with age.
The variation in MSA prevalence could be attributed to differences in demographics, study methodology, diagnostic criteria, and case assessment strategies of MSA.

El texto completo de este artículo está disponible en PDF.

Abstract

Introduction

This paper aims to provide a literature overview on multiple system atrophy (MSA) prevalence in European and other pan-European populations.

Methods

A literature search (PubMed, EMBASE) was performed through 2022 to identify published studies on MSA prevalence in European countries. Of these search results, titles and abstracts were screened for relevance. A standardized assessment tool was used for systematically data extraction and comparison. For studies where only the incidence rate was reported, MSA prevalence was derived based on the incidence and duration of disease.

Results

A total of 24 studies conducted in 14 countries and published between 1995 and 2022 were identified. The prevalence of MSA was reported in 18 (75%) studies and was derived from six (25%) incidence studies. These studies were mainly prospective population-based studies or multi-center studies from specific regions or specialty clinical settings. Two earlier studies in Germany and the Netherlands were conducted using door-to-door design. The time period of evaluation of prevalence ranged from 1990 to 2018. The crude prevalence of MSA ranged from 0.5/100,000 in Spain to 17/100,000 in Japan. Age-specific prevalence rates were provided in five studies, and the reported age ranges varied. The gender-specific crude prevalence was estimated as 2.75/100,000 for men and 1.19/100.000 for women. The derived prevalence was higher (ranging from 0.7–18.9/100,000) than studies where the prevalence was reported.

Conclusion

The variations observed in MSA prevalence may result from differences in age distributions of the study populations, study methodology, diagnostic criteria and case assessment strategies of MSA. Thus, the comparability of these studies is limited.

El texto completo de este artículo está disponible en PDF.

Keywords : Epidemiology, Incidence, Multiple system atrophy, Prevalence


Esquema


© 2024  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 180 - N° 5

P. 438-450 - mai 2024 Regresar al número
Artículo precedente Artículo precedente
  • Prevalence of multiple sclerosis in France in 2021: Data from the French health insurance database
  • C. Pierret, M. Mainguy, E. Leray
| Artículo siguiente Artículo siguiente
  • Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data
  • S. Keovilayhong, A. Mulliez, L. Feral, C. Chenaf, P. Clavelou, X. Moisset, F. Taithe, L. Poncet Megemont

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.